Seattle Genetics upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro upgraded Seattle Genetics to Overweight from Neutral and raised his price target for the shares to $75 from $64. The company reported Q2 Adcetris revenue of $159M, beating consensus of $149M and reversing the trend of low single-digit quarter-over-quarter growth observed over the last three quarters, Catanzaro tells investors in a research note. Further, the analyst's survey work and conversations with key opinion leaders suggests that enfortumab vedotin is poised to see strong uptake in post-chemo/check-point inhibitors UBC. He believes Seattle Genetics' 2019 guidance of $610M-$640M is "well within reach" while it has the opportunity to report positive data from multiple potential registration trials over the next 12 months.